Upon conclusion of this program, learners will have:
an enhanced and deeper understanding of the biologic and clinical rationale for targeting Factor XI in anticoagulation therapy
a working familiarity with the ongoing Phase 3 trial of the FXI inhibitor abelacimab and the process for referring potentially eligible patients for evaluation
